Captrust Financial Advisors Increases Position in Exelixis, Inc. (NASDAQ:EXEL)

Captrust Financial Advisors raised its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 56.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,457 shares of the biotechnology company's stock after purchasing an additional 20,027 shares during the period. Captrust Financial Advisors' holdings in Exelixis were worth $1,847,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB lifted its holdings in Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock worth $63,000 after buying an additional 290 shares during the last quarter. Balyasny Asset Management L.P. raised its position in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock worth $573,000 after acquiring an additional 317 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Exelixis by 4.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after purchasing an additional 330 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in Exelixis by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after purchasing an additional 354 shares during the last quarter. Finally, Principal Securities Inc. boosted its holdings in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 373 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on EXEL shares. Morgan Stanley reissued an "overweight" rating and set a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a report on Wednesday. Stephens reiterated an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Guggenheim reissued a "buy" rating and issued a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Piper Sandler upped their price objective on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Finally, UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and a consensus price target of $38.76.

Exelixis Price Performance

Shares of EXEL stock traded down $0.86 during midday trading on Friday, hitting $45.40. The company had a trading volume of 5,538,335 shares, compared to its average volume of 2,269,019. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $48.85. The company's 50 day simple moving average is $37.06 and its 200 day simple moving average is $35.68. The stock has a market cap of $12.51 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 1.13 and a beta of 0.25.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. The trade was a 14.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 1,508 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $39.00, for a total value of $58,812.00. Following the transaction, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. This trade represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 129,641 shares of company stock worth $4,810,161. Company insiders own 2.82% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.